NICE

News

NICE backs NHS use of Takeda’s Adcetris for rare blood cance...

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form of non-Hodgkin lymphoma (NHL), says NICE.

News

NICE says no to Novartis’ Mayzent in secondary progressive M...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this

Views & Analysis

Getting the most out of technical engagement with NICE

In 2017 the UK’s National Institute for Health and Care Excellence (NICE)

News

NICE backs funding for Roche's lung cancer drug after price ...

NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in final draft guidance.

News

NICE rejects Sanofi's Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance.

Views & Analysis

Teva’s Kim Innes on shaping the post-COVID future with the N...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the